On November 9, 2026 GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE natural killer (NK) cell engager platform, reported preclinical data presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to make progress enrolling patients into our ongoing Phase 1a/1b dose escalation basket trial with GTB-5550 in multiple tumor types", said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "Given the recent advances in this field with KRAS inhibitors becoming a new standard of care and these extremely compelling preclinical results, we are considering all options to conduct a future Phase 1b study combining GTB-5550 with a KRASi in pancreatic cancer patients".
Despite significant recent advances in the field, monotherapy with RAS inhibitors can trigger early resistance via bypass pathways, and the industry is moving more towards the opportunity for multi-drug combinations to provide deeper, more durable responses than single agent KRAS inhibition. The new data demonstrate that GTB-5550 has the potential to improve the effectiveness of KRAS inhibition by making pancreatic cancer cells more susceptible to NK cell cytotoxicity. In orthotopic PDAC xenograft models, the combination of GTB-5550 plus KRASi demonstrated superior tumor control, including complete tumor clearance in several animals, while significantly reducing local invasion and preventing metastasis. When compared to KRASi treatment alone, KRASi + GTB-5550 treatment was associated with a two-fold increase in tumor-infiltration, as well as increases in persistence and CXCR3 expression of adoptively transferred NK cells. This enhanced treatment effect also correlated with a corresponding increase in apoptosis markers on tumor cells.
Oral Presentation Details
Title: Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy
Abstract No.: 655
Presenter: Paarth Dodhiawala, University of Minnesota Medical School1
Date: Friday, November 6, 2026
Time: 3:05-3:20 PM MT
Session 106a: Combination Therapies Involving Cell Therapy, 1:45-3:25 PM MST
Session Description: While cell therapy has transformed the treatment of certain hematologic malignancies, its impact in solid tumors remains limited by antigen heterogeneity, immunosuppressive microenvironments, and nutrient deprivation. As efforts to engineer more effective immune cells continue, there is growing interest in combining cell therapies with complementary approaches to enhance their function and engage endogenous immunity. This session will highlight diverse strategies to extend the clinical impact of cell therapies through rational combination approaches.
(Press release, GT Biopharma, NOV 9, 2026, View Source [SID1234674501])